Dexcom wins FDA approval for next generation of glucose monitors for diabetes

April 6, 2018 by Mike Freeman, The San Diego Union-Tribune

San Diego's Dexcom has won regulatory approval for its latest continuous glucose monitoring system that eliminates the need for finger pricks and is nearly one-third smaller than its current wearable sensor for diabetes patients.

The Food and Drug Administration this week gave the green light to Dexcom's G6 system for delivering real time blood sugar readings. Expected to hit the U.S. market in the second quarter, the G6 targets Type 1 and insulin-taking Type 2 diabetes patients.

"We think G6 carriers are a significant improvement in performance by building on the accuracy and reliability that patients have come to expect from Dexcom continuous monitors," said Chief Executive Kevin Sayer in a conference call with analysts, "including what we believe will be a more consistent experience across all 10 days of use while eliminating the need for routine finger prick calibrations."

The approval was granted three months ahead of schedule, said Kyle Rose, an analyst with Canaccord Genuity. It also ushers in "meaningful product enhancements to help close any competitive gaps from new entrants Libre (from Abbott) and Guardian Connect (from Medtronic,)" said Rose.

Dexcom's shares gained 4.7 percent Wednesday to close at $73.28 on the Nasdaq exchange.

The G6 monitor is worn on the stomach. It contains a small sensor inserted just underneath the skin. The device wirelessly transmits glucose readings every five minutes to a smartphone, smartwatch or medical device app. It will trigger an alarm when a patient's blood sugar soars too high or drops too low.

Last fall, Abbott Labs received FDA approval for its Libre glucose monitory system for adults—challenging Dexcom's market leadership in the U.S. The Libre doesn't require finger pricks and sensors last for 10 days, compared with seven days for Dexcom's previous generation monitors, the G5, which needed finger stick calibration every day or two.

With FDA approval, Dexcom can now match Libre's features. In addition, Dexcom monitors continue to sound an alarm when patients experience blood sugar spikes or crashes—even while they're asleep.

The Libre does not automatically warn users when blood glucose reaches dangerous levels.

Dexcom declined to disclose the price for the G6 system. Insurance firms reimburse for continuous glucose monitoring for Type 1 diabetes, where high can contribute to heart disease, stroke, blindness, kidney failure and nerve damage. Low blood sugar levels can also cause dizziness, unconsciousness and, in extreme cases, death. About 1.4 million Americans are living with Type 1 diabetes, based on research estimates.

Type 2 diabetes is less dangerous but more prevalent, afflicting as many as 27 million Americans. Insurance reimburses for glucose monitors for the most advanced Type 2 patients.

The FDA's approval for Dexcom's G6 monitor allows it to be used as a stand-alone sensor or in conjunction with insulin pumps and other diabetes management devices.

"The ability of this device to work with different types of compatible devices gives patients the flexibility to tailor their diabetes management tools to best meet personal preferences," said Donald St. Pierre, an acting director at the FDA's Center for Devices and Radiological Health.

Data from the G6 can be shared with up to five people, which helps parents of diabetic children keep track of levels. And acetaminophen—the main ingredient in Tylenol—no longer interferes with the monitor's ability to deliver accurate readings.

"The G6 is a whole different platform, and we believe presents a major advancement for the continuous glucose monitoring category," said Sayer.

Baird Equity Research analyst Jeff Johnson said in a research note that less than 30 percent of Type 1 in the U.S. use continuous glucose monitors, where Dexcom is the clear technology leader in the market.

"Simply put, after focusing over the last year or two on concerns about Abbott and to a lesser extent Medtronic, we're starting to believe there are growing opportunities for Dexcom to widen its competitive advantages relative to these competitors," wrote Johnson.

Explore further: FDA OKs continuous blood sugar monitor without finger pricks (Update)

10 shares

Related Stories

FDA OKs continuous blood sugar monitor without finger pricks (Update)

September 28, 2017
U.S. regulators have approved the first continuous blood sugar monitor for diabetics that doesn't need backup finger prick tests.

Fitbit, Dexcom will provide self-management tool for glucose level monitoring

September 10, 2017
(Tech Xplore)—Self-care among people with diabetes is important along with self-monitoring of blood glucose levels. Yet medical problems can trouble some people if they do not manage their diabetes aggressively enough and ...

Blood sugar monitoring system approved for children

February 4, 2014
(HealthDay)—U.S. Food and Drug Administration approval of the Dexcom G4 Platinum Continuous Monitoring System has been expanded to include children with diabetes aged 2 years to 17 years, the agency said.

New study compares two continuous glucose monitoring sensors for effectiveness and patient satisfaction

September 19, 2014
Simultaneous use of two popular continuous glucose monitoring (CGM) sensors revealed clear differences in their accuracy and in patient-rated treatment experiences, including ease of use, feelings of safety, and willingness ...

Big strides made in diabetes care

January 5, 2018
(HealthDay)—This past year was a busy, productive one for diabetes research and care.

Abbott wins FDA approval for diabetes device that doesn't require routine finger pricks

October 4, 2017
Abbott Laboratories has gained clearance to start selling in the U.S. the first continuous glucose monitor that does not require people with diabetes to routinely prick their fingers.

Recommended for you

Genomic study brings us closer to precision medicine for type 2 diabetes

September 21, 2018
Most patients diagnosed with type 2 diabetes are treated with a "one-size-fits-all" protocol that is not tailored to each person's physiology and may leave many cases inadequately managed. A new study by scientists at the ...

High gluten diet in pregnancy linked to increased risk of diabetes in children

September 19, 2018
A high gluten intake by mothers during pregnancy is associated with an increased risk of their child developing type 1 diabetes, suggests a study published by The BMJ today.

Anti-inflammatory protein promotes healthy gut bacteria to curb obesity

September 19, 2018
Scientists from the UNC School of Medicine discovered that the anti-inflammatory protein NLRP12 normally helps protect mice against obesity and insulin resistance when they are fed a high-fat diet. The researchers also reported ...

Study reveals the current rates of diagnosed type 1 and type 2 diabetes in American adults

September 18, 2018
A new study from the University of Iowa finds that type 2 diabetes remains overwhelmingly the most common type of diabetes diagnosed in American adults who have the disease.

Research reveals link between immunity, diabetes

September 14, 2018
When it comes to diet-induced obesity, your immune system is not always your friend.

BPA exposure in U.S.-approved levels may alter insulin response in non-diabetic adults

September 14, 2018
In a first study of its kind study, researchers have found that a common chemical consumers are exposed to several times a day may be altering insulin release. Results of the study, led by scientists at the University of ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.